Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.

By F. A. Moreno, Christoph Wiegand, E. K. Taitano, Pedro L. Delgado. Journal of Clinical Psychiatry, 2006

606 citations recorded by the source corpus.

Subfields: Clinical Psychology, Cognitive Neuroscience, Toxicology

View Paper: https://www.semanticscholar.org/paper/c63abf2d60488970648d6189ae95624b84153202

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Psychology

In Cognitive Neuroscience

In Toxicology

Citations in the corpus

The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs (2014, background): “…state is an exemplar of it, then how does this explain the putative utility of the psychedelic experience e.g., as an adjunct to psychotherapy (Moreno et al., 2006; Grob et al., 2011) and why do some people report being so profoundly affected by such experiences (and often seemingly for the…”
Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression (2017, neutral): “Modern investigations into the therapeutic potential of psychedelics started in the mid-1990s with basic human psychology (Strassman & Qualls, 1994) and neuroimaging research (Vollenweider et al., 1997) before transitioning back into psychiatry in the 2000s (Moreno et al., 2006).”
Psychedelics (2016, methodology): “Moreno et al. (2013) investigated the effects of chronic treatment with the mGlu2/3 receptor inverse antagonist LY341495 [2-[(1S,2S)-2-carboxycyclopropyl]-3(9H-xanthen-9-yl)-D-alanine] on the 5-HT2A receptor– dependent cellular and behavioral responses induced in mice by LSD. Male 129S6/SvEv mice or”
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future (2017, background): “Significant improvements in obsessive compulsive disorder symptoms (Moreno et al, 2006) and alcohol dependence with psilocybin (Bogenschutz et al, 2015), anxiety with LSD (Gasser et al, 2014), and depression with ayahuasca (Osorio Fde et al, 2015; Sanches et al, 2016) help supplement the case for…”
Neuropsychedelia: The Revival of Hallucinogen Research since the Decade of the Brain (2012, background): “26 Samotar refers to the work of Francisco Moreno et al., "Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder," Journal of Clinical Psychiatry 67, no. 11 (2006).”
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up (2017, background): “Psilocybin has shown promise in the treatment of obsessive compulsive disorder (Moreno et al. 2006),”
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. (2011, background): “Researchers concluded that psilocybin is safe and well tolerated in subjects with obsessive-compulsive disorder and may be associated with “robust acute reductions” in core obsessive-compulsive disorder symptoms, although there was no clear doseresponse relationship.(22) During the first wave of hal”